User login
Key clinical point: The combination of upadacitinib and topical corticosteroids (TCS) showed a favorable safety profile in moderate-to-severe atopic dermatitis (AD).
Major finding: Treatment-emergent adverse events (TEAE) were reported by 56% and 64% of patients receiving 15 mg upadacitinib and 30 mg upadacitinib, respectively, vs. 42% of patients receiving placebo. Mild/moderate acne was more frequent with 15 mg upadacitinib (13.2%) and 30 mg (19.8%) vs. placebo (5.6%), but did not lead to treatment discontinuation. No new safety risks or deaths were reported.
Study details: Findings are a 24-week interim safety analysis of an ongoing phase 3 Rising Up trial including 272 patients with moderate-to-severe AD with an inadequate response to systemic treatment who were randomly assigned to 15 mg upadacitinib, 30 mg upadacitinib, or placebo, all in combination with TCS.
Disclosures: This study was funded by AbbVie. The authors declared serving as speakers, consultants, and investigators or receiving honoraria, grants, funding, and scholarship from various sources. Six authors declared being employees or shareholders of AbbVie.
Source: Katoh N et al. JAAD Int. 2021 (Dec 19). Doi: 10.1016/j.jdin.2021.11.001.
Key clinical point: The combination of upadacitinib and topical corticosteroids (TCS) showed a favorable safety profile in moderate-to-severe atopic dermatitis (AD).
Major finding: Treatment-emergent adverse events (TEAE) were reported by 56% and 64% of patients receiving 15 mg upadacitinib and 30 mg upadacitinib, respectively, vs. 42% of patients receiving placebo. Mild/moderate acne was more frequent with 15 mg upadacitinib (13.2%) and 30 mg (19.8%) vs. placebo (5.6%), but did not lead to treatment discontinuation. No new safety risks or deaths were reported.
Study details: Findings are a 24-week interim safety analysis of an ongoing phase 3 Rising Up trial including 272 patients with moderate-to-severe AD with an inadequate response to systemic treatment who were randomly assigned to 15 mg upadacitinib, 30 mg upadacitinib, or placebo, all in combination with TCS.
Disclosures: This study was funded by AbbVie. The authors declared serving as speakers, consultants, and investigators or receiving honoraria, grants, funding, and scholarship from various sources. Six authors declared being employees or shareholders of AbbVie.
Source: Katoh N et al. JAAD Int. 2021 (Dec 19). Doi: 10.1016/j.jdin.2021.11.001.
Key clinical point: The combination of upadacitinib and topical corticosteroids (TCS) showed a favorable safety profile in moderate-to-severe atopic dermatitis (AD).
Major finding: Treatment-emergent adverse events (TEAE) were reported by 56% and 64% of patients receiving 15 mg upadacitinib and 30 mg upadacitinib, respectively, vs. 42% of patients receiving placebo. Mild/moderate acne was more frequent with 15 mg upadacitinib (13.2%) and 30 mg (19.8%) vs. placebo (5.6%), but did not lead to treatment discontinuation. No new safety risks or deaths were reported.
Study details: Findings are a 24-week interim safety analysis of an ongoing phase 3 Rising Up trial including 272 patients with moderate-to-severe AD with an inadequate response to systemic treatment who were randomly assigned to 15 mg upadacitinib, 30 mg upadacitinib, or placebo, all in combination with TCS.
Disclosures: This study was funded by AbbVie. The authors declared serving as speakers, consultants, and investigators or receiving honoraria, grants, funding, and scholarship from various sources. Six authors declared being employees or shareholders of AbbVie.
Source: Katoh N et al. JAAD Int. 2021 (Dec 19). Doi: 10.1016/j.jdin.2021.11.001.